AstraZeneca Selloff Looks Larger Than the Wainua Valuation Damage

AstraZeneca's stock plummeted 5.7% after its Phase 3 CARDIO-TTRansform trial for heart drug Wainua failed to meet its primary endpoint, erasing $24 billion in market value. However, analysts argue the selloff is an overcorrection, as the failed program represents only ~2% of the company's net present value. The fundamental business remains intact with strong margins, existing drug approvals unchanged, and the $80 billion 2030 revenue target untouched. The market punished the company more for a credibility crack than actual financial damage.